Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study

Manuel Sureda González; Joseba Rebollo Liceaga; Elena María Martínez Navarro; Francisco José Fernández Morejón; José Farré Alegre; Vicente Muñoz Madero; Pere Bretcha Boix; Maritza Duarte; Ramón González Manzano; Aurora Crespo de la Jara; M. C. Redal Peña; Belén Valenzuela Jiménez; Antonio Brugarolas Masllorens

Ayuda

Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study

M. Sureda ^[2] ; J. Rebollo ^[1] ; E. Mª. Martínez-Navarro ^[2] ; F. J. Fernández-Morejón ^[2] ; J. Farré ^[2] ; V. Muñoz ^[2] ; P. Bretcha-Boix ^[2] ; M. Duarte ^[2] ; R. G. Manzano ^[2] ; A. Crespo ^[2] ; M. del Carmen Redal ^[2] ; B. Valenzuela ^[2] ; A. Brugarolas ^[2]
1. [1] Hospital General de Villalba
  
  Hospital General de Villalba
  
  Collado Villalba, España
2. [2] Hospital Quironsalud Torrevieja, España
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 6 (June 2018), 2018, págs. 785-793
Idioma: inglés
Texto completo no disponible (Saber más ...)
Resumen
- Purpose The present study evaluates the massive study of gene expression in metastatic breast carcinoma (MBC) patients using microarray gene expression profiling (MAGE) complemented with conventional sequencing, immunohistochemistry (IHC) and fluorescent “in situ” hybridization (FISH), seeking to optimize the treatment in a subset of heavily pretreated patients and with limited life expectancy.
  
  Patients, material and methods MBC patients in hormone therapy progression with survival expectancy of at least 3 months (m) have been included. The MAGE contains gene probes representing genes known to potentially interact with available drugs as cited in the literature.
  
  Results Thirty-nine procedures were performed from October 2010 to April 2016. Within the 30 evaluable procedures, considering all hormonal manipulations as a single line, the patients had received a median of 4 treatment lines prior to MAGE (range 1–7). Progression was observed in 6 cases, stable disease (SD) in 7 cases and partial response (PR) in 16 cases, which implies a clinical benefit rate (SD + PR) of 76%. Actuarial median progression-free survival (PFS) was 6 m (95% CI 2.5–9.5) in patients with clinical benefit. The median overall survival (OS) for the entire series was 11 m (95% CI 2.2–19.8).
  
  Conclusion Data presented here indicate that the use of MAGE provides relevant information to establish personalized treatment in frail patients with limited life expectancy in which therapeutic futility is a particularly difficult burden to assume.